The9 Limited (NASDAQ:NCTY) shares remains unchanged in last trading session and ended the day at $2.27. NCTY Gross Margin is -33.30% and its has a return on assets of -66.70%. The9 Limited (NASDAQ:NCTY) quarterly performance is -39.79%.
The9 Limited (NASDAQ: NCTY), announced that it has entered into a memorandum of understanding (“MOU”) with L&A International Holding Limited, a Cayman Islands company with shares listed on the Growth Enterprise Market of the Stock Exchange of Hong Kong Limited under stock code 8195 (“L&A”), and certain other shareholders of Red 5, to exchange approximately 30.6% equity interest (the “Swapped Red 5 Interest”) that it owns in its subsidiary Red 5 Studios, Inc. (“Red 5”) for such number of newly issued shares of L&A which has the same value as the Swapped Red 5 Shares.
Unisys Corporation (NYSE:UIS) ended the last trading day at $7.31. Company weekly volatility is calculated as 7.97% and price to cash ratio as 1.00. Unisys Corporation (NYSE:UIS) showed a weekly performance of -33.73%.
Unisys Corporation (NYSE:UIS) announced the pricing of $190 million aggregate principal amount of Convertible Senior Notes due 2021 (the “notes”) through a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Unisys granted the initial purchasers an option to purchase up to an additional $28.5 million in aggregate principal amount of the notes on the same terms and conditions, solely to cover over-allotments, if any. The offering size was increased to $190 million from the previously announced amount of $150 million, and the option granted to the initial purchasers was increased to $28.5 million from the previously announced amount of $22.5 million.
On 15 March, Sequenom Inc. (NASDAQ:SQNM) shares fell -5.10% and was closed at $1.49. SQNM EPS growth in last 5 year was 39.20%. Sequenom Inc. (NASDAQ:SQNM) year to date (YTD) performance is -9.15%.
On 2 March, Sequenom Inc. (NASDAQ:SQNM) reported Revenue for the fourth quarter of 2015 was $27.8 million, compared to $29.9 million for the third quarter of 2015 and $36.8 million for the fourth quarter of 2014. Revenue is recorded primarily on a cash basis, with accrual accounting used for several third-party payors and for client bill arrangements. The decline in revenue in the fourth quarter of 2015 compared to the third quarter is attributed to reimbursement rates and timing of cash collections. Diagnostic services revenue for the fourth quarter of 2015 was approximately $6.6 million lower than the same period in 2014 as a result of the transition of certain customers to licensee status, which contributed to the increase in license fee revenue.
SeaDrill Limited (NYSE:SDRL) shares fell -8.25% in last trading session and ended the day at $3.56. SDRL Gross Margin is 60.60% and its has a return on assets of -3.00%. SeaDrill Limited (NYSE:SDRL) quarterly performance is -14.42%.
Seadrill Limited (NYSE:SDRL) has settled a Total Return Swap agreement (TRS) expiring on March 3, 2016 with 4,000,000 common shares in Seadrill Limited as underlying security. Seadrill has subsequently entered into a new TRS agreement with exposure to 4,000,000 Seadrill Limited common shares. The expiry date for the new TRS is June 3, 2016 and the reference price is NOK21.1611 per share.
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) caters to the Healthcare space. Its weekly performance is 28.87%. On the last day of trading company shares ended up at $3.08.
On 2 March, Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for voclosporin, the Company’s next generation calcineurin inhibitor, for the treatment of Lupus Nephritis (LN).
Leave a Reply